Programmed-Cycle Frozen Embryo Transfer as a Risk Factor for PAS – RBMO
Reproductive BioMedicine Online (RBMO) shared a post on LinkedIn:
“While previous studies have investigated the risk of placenta accreta spectrum (PAS) following either Programmed- or Natural-Cycle Frozen Embryo Transfer (PC-FET/NC-FET), this new paper from Tomoyuki Fujita and team in Japan, is the first to compare the risk of PAS between Programmed, Natural, and Stimulated-cycles, with fresh embryo transfer.
The findings indicated that, among all the FET groups, only PC-FET was associated with a significantly higher risk of PAS compared with fresh embryo transfer.
The authors suggest that the incidence of PAS is not attributable to FET techniques per se, but rather to the endometrial preparation protocols applied, and reproductive physicians should recognize that PC-FET is a risk factor for PAS when planning embryo transfer.
RBMO subscribers can read the full paper from our in-press articles section now.”
Title: Risk of placenta accreta spectrum in fresh versus natural, stimulated and programmed cycle frozen-thawed embryo transfer
Authors: Tomoyuki Fujita, Toshiyuki Yoshizato, Kenta Murotani, Hitoshi Obara, Naotake Tsuda
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Apr 17, 2026, 04:19WHO Raises Alarm Over Global Burden of Child Marriage
-
Apr 17, 2026, 04:11Sign Up for Our Latest BFS Insights Webinar – British Fertility Society
-
Apr 17, 2026, 03:43Chantelle Pereira: Endometriosis Paper Highlights Diagnostic Delays and Gaps in Patient Care
-
Apr 17, 2026, 03:35Tal Varsano: Plasma Proteomic Signature of the Human Menstrual Cycle
-
Apr 17, 2026, 03:30Vacancy for a Friendly Senior Embryologist in Berlin, Germany – ESHRE
-
Apr 17, 2026, 03:05Clinical Study Supports Continued IVF After Unsuccessful First Transfer – RBMO
-
Apr 17, 2026, 02:57Standing Together for Black Maternal Health Week – ACOG
-
Apr 16, 2026, 17:24No Difference Between Natural and Artificial Cycles in Endometrium Cases – RBMO
-
Apr 16, 2026, 17:20Marco Zaccaria: Recognizing Innovation in Adenomyosis Treatment